281 related articles for article (PubMed ID: 32543364)
1. Efficacy and Safety of Evolocumab in Reducing Low-Density Lipoprotein Cholesterol Levels in Chinese Patients with Non-ST-segment Elevation Acute Coronary Syndrome.
Xu X; Chai M; Cheng Y; Peng P; Liu X; Yan Z; Guo Y; Zhao Y; Zhou Y
Curr Vasc Pharmacol; 2021; 19(4):429-437. PubMed ID: 32543364
[TBL] [Abstract][Full Text] [Related]
2. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Koskinas KC; Windecker S; Pedrazzini G; Mueller C; Cook S; Matter CM; Muller O; Häner J; Gencer B; Crljenica C; Amini P; Deckarm O; Iglesias JF; Räber L; Heg D; Mach F
J Am Coll Cardiol; 2019 Nov; 74(20):2452-2462. PubMed ID: 31479722
[TBL] [Abstract][Full Text] [Related]
3. Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Zhang Y; Zhang Y; Zhang B; Chen Z; Wei Y; Chen P; Chang C; Liu G; Chen K; Ding J; Jiang Z
Clin Ther; 2022 Jun; 44(6):901-912. PubMed ID: 35581018
[TBL] [Abstract][Full Text] [Related]
4. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
Hao Y; Yang YL; Wang YC; Li J
Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
[TBL] [Abstract][Full Text] [Related]
5. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial.
Koskinas KC; Windecker S; Buhayer A; Gencer B; Pedrazzini G; Mueller C; Cook S; Muller O; Matter CM; Räber L; Heg D; Mach F;
Clin Cardiol; 2018 Dec; 41(12):1513-1520. PubMed ID: 30421481
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
7. Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH).
Han Y; Ren L; Fei X; Wang J; Chen T; Guo J; Wang Q
Atherosclerosis; 2024 Apr; 391():117471. PubMed ID: 38493669
[TBL] [Abstract][Full Text] [Related]
8. Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol.
Gao J; Liu JY; Lu PJ; Xiao JY; Gao MD; Li CP; Cui Z; Liu Y
Front Physiol; 2021; 12():750872. PubMed ID: 34887772
[No Abstract] [Full Text] [Related]
9. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
10. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.
Baum SJ; Sampietro T; Datta D; Moriarty PM; Knusel B; Schneider J; Somaratne R; Kurtz C; Hohenstein B
J Clin Lipidol; 2019; 13(6):901-909.e3. PubMed ID: 31759938
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
[TBL] [Abstract][Full Text] [Related]
12. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
Zhao SP; Yu BL; Peng DQ; Huo Y
Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
[TBL] [Abstract][Full Text] [Related]
13. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
Liu Y; Han B
Transpl Immunol; 2022 Apr; 71():101444. PubMed ID: 34375677
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin.
Ran D; Nie HJ; Gao YL; Deng SB; Du JL; Liu YJ; Jing XD; She Q
Int J Cardiol; 2017 May; 235():49-55. PubMed ID: 28291622
[TBL] [Abstract][Full Text] [Related]
15. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
[TBL] [Abstract][Full Text] [Related]
16. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
[TBL] [Abstract][Full Text] [Related]
17. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS; Giugliano RP; Keech AC; Honarpour N; Wiviott SD; Murphy SA; Kuder JF; Wang H; Liu T; Wasserman SM; Sever PS; Pedersen TR;
N Engl J Med; 2017 May; 376(18):1713-1722. PubMed ID: 28304224
[TBL] [Abstract][Full Text] [Related]
18. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
19. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
Yano H; Horinaka S; Ishimitsu T
J Cardiol; 2020 Mar; 75(3):289-295. PubMed ID: 31495548
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.
Shah CP; Shah BP; Dani SI; Channa BB; Lakshmanan SS; Krishnamani NC; Mehta A; Moorthy P
Indian Heart J; 2016; 68(6):766-771. PubMed ID: 27931543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
